p53 down-regulation: a new molecular mechanism involved in ischaemic preconditioning

被引:46
作者
Mocanu, MM
Yellon, DM [1 ]
机构
[1] UCL, Sch Med, Hatter Inst, London WC1E 6DB, England
[2] UCL, Sch Med, Ctr Cardiol, London WC1E 6DB, England
关键词
phosphatidylinositol 3-kinase-Akt pathway; Mdm2; phosphorylation; p53; downregulation; myocardial ischemia; ischemic preconditioning;
D O I
10.1016/S0014-5793(03)01260-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ischaemic preconditioning is associated with the activation of prosurvival mechanisms. Here we demonstrate that following a preconditioning protocol, the proapoptotic p53 is inactivated possibly via phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt)-murine double minute 2 (Mdm2) phosphorylation. Our data show that in preconditioned hearts Mdm2 was significantly phosphorylated, and wortmannin (a PI3K inhibitor) abrogated this effect (Western blotting). Also in preconditioned hearts p53 was shown to be bound to phospho-Mdm2 (co-immunoprecipitation). Furthermore, pifithrin alpha (a p53 inhibitor), administered to isolated perfused hearts prior to ischaemia, significantly attenuated the infarction. In conclusion our results suggest that p53 is implicated in ischaemia/reperfusion injury and that preconditioning counterbalances this effect via PI3K-Akt-Mdm2 phosphorylation. (C) 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
引用
收藏
页码:302 / 306
页数:5
相关论文
共 22 条
[1]   p53-Mdm2 - the affair that never ends [J].
Alarcon-Vargas, D ;
Ronai, Z .
CARCINOGENESIS, 2002, 23 (04) :541-547
[2]   Regulation of p53 stability [J].
Ashcroft, M ;
Vousden, KH .
ONCOGENE, 1999, 18 (53) :7637-7643
[3]   Phosphorylation of HDM2 by Akt [J].
Ashcroft, M ;
Ludwig, RL ;
Woods, DB ;
Copeland, TD ;
Weber, HO ;
MacRae, EJ ;
Vousden, KH .
ONCOGENE, 2002, 21 (13) :1955-1962
[4]   Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart [J].
Baines, CP ;
Wang, L ;
Cohen, MV ;
Downey, JM .
BASIC RESEARCH IN CARDIOLOGY, 1999, 94 (03) :188-198
[5]   Multiple roles of the tumor suppressor p53 [J].
Bargonetti, J ;
Manfredi, JJ .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (01) :86-91
[6]   A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β-peptide [J].
Culmsee, C ;
Zhu, XX ;
Yu, QS ;
Chan, SL ;
Camandola, S ;
Guo, ZH ;
Greig, NH ;
Mattson, MP .
JOURNAL OF NEUROCHEMISTRY, 2001, 77 (01) :220-228
[7]   Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis [J].
Gottlieb, TM ;
Leal, JFM ;
Seger, R ;
Taya, Y ;
Oren, M .
ONCOGENE, 2002, 21 (08) :1299-1303
[8]   Deconstruction of p53 functions and regulation [J].
Ygal Haupt ;
Ana I Robles ;
Carol Prives ;
Varda Rotter .
Oncogene, 2002, 21 (54) :8223-8231
[9]   Medical and cellular implications of stunning, hibernation, and preconditioning - An NHLBI Workshop [J].
Kloner, RA ;
Bolli, R ;
Marban, E ;
Reinlib, L ;
Braunwald, E ;
Reinlib, LJ ;
Bonow, RO ;
Borgers, M ;
Downey, J ;
Feigenbaum, H ;
Ganote, C ;
Gross, G ;
Jennings, R ;
Levitsky, S ;
McCully, JD ;
Mentzer, R ;
Miller, WP ;
Przyklenk, K ;
Rahimtoola, S ;
Vatner, S ;
Yellon, D .
CIRCULATION, 1998, 97 (18) :1848-1867
[10]   A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy [J].
Komarov, PG ;
Komarova, EA ;
Kondratov, RV ;
Christov-Tselkov, K ;
Coon, JS ;
Chernov, MV ;
Gudkov, AV .
SCIENCE, 1999, 285 (5434) :1733-1737